Sun Pharma Agrees $11.75B Deal to Acquire Organon, Marking Largest M&A Transaction of 2026
Indian generics giant Sun Pharmaceutical Industries signed a definitive agreement in April 2026 to acquire U.S. healthcare company Organon & Co. for approximately $11.75 billion. The deal — the largest M&A transaction of 2026 to date — gives Sun Pharma access to Organon's biosimilars portfolio, women's health franchises, and commercial operations across 140+ markets worldwide.
Gilead Sciences Acquires ADC Biotech Tubulis for Up to $5B to Expand Oncology Pipeline
Gilead Sciences agreed on 7 April 2026 to acquire Munich-based antibody-drug conjugate biotech Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestones. Tubulis's lead asset TUB-040 targets NaPi2b-expressing tumours, showing a 59% overall response rate in platinum-resistant ovarian cancer. The deal is part of Gilead's broader pivot toward oncology through a string of spring 2026 acquisitions.
Gilead Sciences Acquires CAR-T Developer Arcellx for $7.8B in Haematology Push
Gilead Sciences closed its $7.8 billion acquisition of CAR-T therapy developer Arcellx in April 2026. Arcellx's lead asset anito-cel targets relapsed/refractory multiple myeloma — a competitive indication — with Phase 3 data and an expected FDA filing later this year. Post-close, Gilead trimmed approximately 192 positions at Arcellx's Redwood City and Rockville sites as integration began.
Gilead Sciences Acquires Ouro Medicines for $2.18B to Enter T-Cell Engager Autoimmune Market
Gilead Sciences agreed in April 2026 to acquire Ouro Medicines for up to $2.18 billion, gaining a novel T-cell engager platform targeting autoimmune diseases including rheumatoid arthritis, lupus, and inflammatory bowel disease. The deal marks Gilead's entry into immunology beyond its virology roots and completes a six-week acquisition spree — alongside Arcellx and Tubulis — that will generate $11.5 billion in 2026 acquisition charges.